These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 12200353

  • 21. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S.
    Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595
    [Abstract] [Full Text] [Related]

  • 22. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
    Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, Yagasaki F, Kawai Y, Miyawaki S, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group.
    Blood; 2004 Dec 01; 104(12):3507-12. PubMed ID: 15315963
    [Abstract] [Full Text] [Related]

  • 23. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S, Kim YJ, Min CK, Kim HJ, Eom KS, Kim DW, Lee JW, Min WS, Kim CC.
    Blood; 2005 May 01; 105(9):3449-57. PubMed ID: 15657178
    [Abstract] [Full Text] [Related]

  • 24. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.
    Roche-Lestienne C, Deluche L, Corm S, Tigaud I, Joha S, Philippe N, Geffroy S, Laï JL, Nicolini FE, Preudhomme C, Fi-LMC group.
    Blood; 2008 Apr 01; 111(7):3735-41. PubMed ID: 18202228
    [Abstract] [Full Text] [Related]

  • 25. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
    Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima M.
    Blood; 2006 Aug 15; 108(4):1421-3. PubMed ID: 16601247
    [Abstract] [Full Text] [Related]

  • 26. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
    de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, Réa D, Cayuela JM, Vekemans MC, Reman O, Buzyn A, Pigneux A, Escoffre M, Chalandon Y, MacIntyre E, Lhéritier V, Vernant JP, Thomas X, Ifrah N, Dombret H, Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).
    Blood; 2007 Feb 15; 109(4):1408-13. PubMed ID: 17062730
    [Abstract] [Full Text] [Related]

  • 27. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
    Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, Lange T, Hochhaus A, Wystub S, Brück P, Hoelzer D, Ottmann OG.
    Blood; 2007 Jul 15; 110(2):727-34. PubMed ID: 17405907
    [Abstract] [Full Text] [Related]

  • 28. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
    Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Cheron N, Maloisel F, Mahon FX, Facon T, Berthaud P, Guilhot J, Guilhot F, CML French Group.
    Blood; 2003 Dec 15; 102(13):4298-305. PubMed ID: 12933584
    [Abstract] [Full Text] [Related]

  • 29. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
    Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M.
    Blood; 2007 Apr 15; 109(8):3207-13. PubMed ID: 17185463
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.
    Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B, Duyster J, Peschel C, Kirkpatrick CJ, Theobald M, Gschaidmeier H, Huber C, Fischer T.
    Blood; 2004 May 15; 103(10):3644-54. PubMed ID: 14726395
    [Abstract] [Full Text] [Related]

  • 31. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
    Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Brümmendorf TH, Matczak E, Bardy-Bouxin N, Shapiro M, Turnbull K, Leip E, Cortes JE.
    Am J Hematol; 2015 Sep 15; 90(9):755-68. PubMed ID: 26040495
    [Abstract] [Full Text] [Related]

  • 32. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
    Ito K, Tominaga K, Suzuki T, Jinnai I, Bessho M.
    Int J Hematol; 2005 Apr 15; 81(3):242-5. PubMed ID: 15814335
    [Abstract] [Full Text] [Related]

  • 33. Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Hoelzer D, Gökbuget N, Ottmann OG.
    Semin Hematol; 2002 Oct 15; 39(4 Suppl 3):32-7. PubMed ID: 12447850
    [Abstract] [Full Text] [Related]

  • 34. Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia.
    Hato T, Yamanouchi J, Tamura T, Hojo N, Niiya Y, Kohno M, Bando S, Yakushijin Y, Takada K, Sakai I, Yasukawa M, Fujita S.
    Int J Hematol; 2004 Jul 15; 80(1):62-6. PubMed ID: 15293570
    [Abstract] [Full Text] [Related]

  • 35. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
    Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, Rios MB, Faderl S, Verstovsek S, Ferrajoli A, Freireich EJ, Talpaz M, Kantarjian H.
    Blood; 2003 Jul 01; 102(1):83-6. PubMed ID: 12637317
    [Abstract] [Full Text] [Related]

  • 36. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).
    Leis JF, Stepan DE, Curtin PT, Ford JM, Peng B, Schubach S, Druker BJ, Maziarz RT.
    Leuk Lymphoma; 2004 Apr 01; 45(4):695-8. PubMed ID: 15160941
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M.
    Clin Ther; 2007 Nov 01; 29(11):2289-308. PubMed ID: 18158072
    [Abstract] [Full Text] [Related]

  • 39. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy.
    Bujassoum S, Rifkind J, Lipton JH.
    Leuk Lymphoma; 2004 Feb 01; 45(2):401-3. PubMed ID: 15101732
    [Abstract] [Full Text] [Related]

  • 40. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
    Koh Y, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, Lee KH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Chung J, Shin HJ, Kim SH, Kim CS, Song HS, Kim MK, Hyun MS, Ahn JS, Jung CW, Park S, Korean Society of Hematology CML working party.
    Ann Hematol; 2010 Jul 01; 89(7):725-31. PubMed ID: 20179930
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.